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Glioblastoma is the most common and deadly human brain cancers. Unique barriers hinder the drug
delivering pathway due to the individual position of glioblastoma, including blood-brain barrier and
blood-brain tumor barrier. Numerous bioactive materials have been exploited and applied as the
transvascular delivery carriers of therapeutic drugs. They promote site-speciﬁc accumulation and long
term release of the encapsulated drugs at the tumor sites and reduce side effects with systemic delivery.
And the delivery systems exhibit a certain extent of anti-glioblastoma effect and extend the median
survival time. However, few of them step into the clinical trials. In this review, we will investigate the
recent studies of bioactive materials for glioblastoma chemotherapy, including the inorganic materials,
lipids and polymers. These bioactive materials construct diverse delivery vehicles to trigger tumor sites
in brain intravenously. Herein, we exploit their functionality in drug delivery and discuss the deﬁciency
for the featured tumors, to provide guidance for establishing optimized therapeutic drug formulation for
anti-glioblastoma therapy and pave the way for clinical application.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Glioblastoma is the most common and malignant primary brain
tumors. The median survival time of the patients is only 14.6
months after diagnosis, and the 5-year survival rate is less than 10%
[1,2]. Glioblastoma cells rarely metastasize to other body organs,
but they exhibit high aggressiveness and inﬁltration in brain tissues
[3]. With these features, surgical resection cannot completely
eliminate the tumor, and unavoidably leads to recurrence [4].
Numerous therapeutic agents, including chemical drugs, pro-
teins and gene drugs, have emerged to show great potential to treat
glioblastoma [5e7]. Like temozolomide (TMZ), a derivative of the
alkylating agent dacarbazine, has been approved by oral adminis-
tration for treating the newly diagnosed and recurrent malignant
glioma [8e10]. However, the oral route offers insufﬁcient drug
concentration, and high daily doses leads to tumor resistance to the
alkylating agents [11]. Due to the characteristics of the anti-tumor
drugs, they always have poor solubility, short circulation and
quick clearance. Most importantly, unlike other tumors, the intra-
cranial tumors set up unique barriers to hinder effective therapy
due to their individual position [12]. One is the blood-brain barrier
(BBB), which is composed of brain endothelial cells, pericytes and
astrocytic endfeet. It undertakes the responsibility to strictly
regulate the transportation of large and small molecules between
the blood and the brain parenchyma [13]. This structure is very
essential to protect the healthy brain and prevent toxic trans-
portation from blood [14]. However, it also impairs drug delivery
into the lesion in the brain for effective therapy. The other one is the
blood-brain tumor barrier (BTB), which refers to the transport ob-
stacles between the blood vessels and brain tumor cells [15,16]. The
blood vessels around the glioblastoma had the similar features with
vessels in other tumor microenvironment, like permeability for
drug entry. And the brain tumor cells also express transport protein
for drug efﬂux. Due to these barriers in brain tumors, it is generally
difﬁcult for the free drugs to get appropriate targeting and suitable
delivery penetrating into the glioma parenchyma. These all result in
poor therapeutic responses against the tumor and severe side-
effects to normal tissues. Herein, a more efﬁcient strategy isFig. 1. The chemical structure of TAT-Au NP-DOX, and the release process under aurgently needed for glioblastoma therapy.
Recently, a variety of biomaterials has been exploited and
applied as agents and delivery vehicles [17], including inorganic
materials, lipids and polymers. They are widely used to overcome
the problems including drug solubility and stability, and long cir-
culation. They could be easily modiﬁed and manufactured to
construct a more suitable and efﬁcient delivery system for glio-
blastoma. With the development of nanotechnology, the drug de-
livery system could trigger these drugs to the tumor sites with
minimal adverse effects. There had some reviews reported about
the glioblastoma therapy. For example, Buddy D. Ratner's group
detailed the intracranial tumor therapy by a localized application of
polymeric microspheres with encapsulated drugs [18]. GLIADEL®
wafer was the only FDA approved product for locally intracranial
tumor therapy at the site of tumor resection, and its application for
treatment of glioblastoma had been reported by Scott D. Wait et al.
[19]. The therapeutic strategies and drug delivery process with
nanoparticles against brain cancers had also covered in previous
reports [20,21]. However, these reviews didn't exploit the struc-
tures and functionality of the applied bioactive materials for glio-
blastoma therapy via intravenous injection (i.v.). Here, in this
review, we will focus on the bioactive materials applied in the
treatment of glioblastoma, exploit their functionality in drug de-
livery and deﬁciency and discuss the inﬂuence of material struc-
tures on the transvascular transportation for drug delivery to brain
tumors, to provide guidance for development of rational delivery
vectors for effective anti-glioblastoma therapy.2. Inorganic material-based nanoparticles
Many inorganic biomaterials were exploited as delivery plat-
forms to deliver therapeutic drugs [22e24]. They could regulate the
size of nanoparticles to overcome the limitation of unique struc-
tures of brain tumors. For example, Maciej S. Lesniak et al. exploited
a blood-brain barrier permeable platform with ultra-small gold
nanoparticles (5 nm) to deliver anticancer drug doxorubicin (DOX)
to brain tumor tissues (Fig. 1) [25]. The pH-sensitive Au nano-
particles modiﬁed with a transactivator of transcription (TAT)cidic conditions. Reprinted and modiﬁed with the permission from Ref. [25].
Fig. 2. Illustration of the controlled assembly of multicomponent nanochain by using
solid-phase chemistry. Firstly, janus-faced iron oxide nanospheres with two functional
groups were synthesized (a). Secondly, the unique faces on the nanospheres conju-
gated together and chemically linked with a DOX-loading liposome (b). Reprinted with
permission from Ref. [37].
J. Yang et al. / Bioactive Materials 1 (2016) 29e38 31peptide, and brought the drug penetrate through BBB and reach the
tumor. Comparing with free drug group (37.5 days), the median
survival of TAT-Au NP-DOX treated group was 44 days after a single
administration by i.v. injection in an intracranial U87 mouse model.
Ultra-small sized metal nanoparticles could be easily prepared.
This provided better condition for this sized nanoparticles getting
into the brain [26]. However, this nanoparticles also facilitate entryFig. 3. The chemical structures of the synthesized cationinto normal organs, like liver and kidney, without a suitable guid-
ance [27]. Moreover, these metal-based nanoparticles are mostly
non-biodegradable, which might induce metabolic problem and
side-toxicity to human body [26,28]. Herein, the proper target and
optimized clearance are the important parameters for the design
and application of inorganic material-based system for glioblas-
toma therapy.3. Liposomes
Liposomes were promising delivery vesicles composed of lipid
bilayers [29]. They had spherical structures, and formed a hydro-
philic cavity with the lipid bilayers. The size of the liposomes could
be varied from nanometers to micrometers. The ﬁrst liposomal
drug, Doxil (doxorubicinHCl liposome injection), was approved by
FDA to treat ovarian cancer, AIDS-related Kaposi's sarcoma, and
multiple myeloma [30]. From then on, the delivery of therapeutic
drugs with liposome had attracted intensive attentions for anti-
cancer application [31e33]. For example, Efstathios Karathanasis's
group developed amulticomponent nanochain carrier to access the
brain and accumulate at the glioma sites [34]. This nanochain was
composed of a DOX-loading DSPE-PEG/DPPC/cholesterol liposome
and three iron oxide nanospheres by using a two-step solid-phase
chemistry (Fig. 2) [35e37]. The hydrodynamic diameter of the
liposome was 35 nm, and the iron oxide nanospheres was 27 nm,
with the iron oxide core only 10 nm. The unique linear assembly
modiﬁed with a c(RGDfC) peptide as a targeting ligand for avb3
integrin receptor, which resulted in 18.6-fold increase of drug
accumulation in brain tumors. With the assistant of a radio-
frequency ﬁeld, the encapsulated drug could quickly release by the
oscillation the iron oxide. And the survival time of the nanochain
treated group extended to 25 ± 3 days, 2.5-fold increase inic lipids. Reprinted with permission from Ref. [39].
J. Yang et al. / Bioactive Materials 1 (2016) 29e3832comparison with the DOX treated group in highly invasive CNS-1
(central nervous system-1) model.
In order to trigger site-speciﬁc release and enhance drug accu-
mulation in tumor sites, many stimuli-sensitive lipids were
designed and constructed to form multifunctional formulations.
Thomas L Andresen et al. designed a matrix metalloproteinases
(MMPs)-sensitive lipid nanoparticle, which could be cleaved in the
tumor microenvironment [38]. The PEGylated cleavable lipid
nanoparticles decorated with angiopep ligand on the surfaces,
which targeted to the low-density lipoprotein receptor-related
protein-1 expressed on the blood-brain barrier. The hydrody-
namic diameter of the nanoparticles was around 100e200 nm after
angiopep functionalization. The siRNA delivery system induced 10-
fold higher uptake than non-targeted nanoparticles, and compa-
rable gene knockdown with the commercial agent RNAiMAX,
which was used as standard for in vitro siRNA delivery.
Recently, Zheng-Rong Lu et al. developed a series of pH-
sensitive, amphiphilic cationic lipids as nucleic acid carriers [39].
The lipids possessed three structural domains: a protonable amine-
based head group (R1), a hydrophobic tail containing two long-
chain unsaturated fatty acids (R2) and cysteine-based linker
group (Fig. 3). The unique characteristic of the carrier endowed the
formed nanoparticles with multifunctional properties, such as
electrostatic binding, pH-sensitive and reducible-sensitive. The
lead cationic carrier, ECO ((1-aminoethyl) iminobis[N-(oleicylcys-
teinyl-1-amino-ethyl)-propionamide]), was emerged for siRNA
delivery into U87 glioblastoma cells [40]. The particle diameter of
ECO/siRNA nanoparticles decreased while their zeta potential
increased as the N/P ratio increased. The nanoparticles could
readily escaped from endosomes, and exhibited potential and
sustained gene silencing in vitro. However, liposomeswere prone to
liver accumulation without a direction [41,42]. Herein, selective
targeting should be required to cross the brain barriers and trans-
port drug into glioblastoma for further studies [43].
Though the liposomes make huge studies to investigate the
application in human diseases, there still have some problems need
to solve, including the in vivo instability, poor reproducibility in
formulation and relatively higher cost to production [29,44]. These
all hinder the clinical application of liposomes. Moreover, for glio-
blastoma therapy, there have other aspects need to consider as li-
posomes. Due to the individual position of the brain tumor, the
diameter and stability of the liposomes should be optimized to
cross the BBB and facilitate to localize at the tumor sites with suf-
ﬁcient drug concentration.
4. Polymer nanoparticles
Due to their potential of diversiﬁed structures and feasible
functionality, polymer carriers are promising vectors to overcome
the brain barriers for therapeutic drugs delivery. Many bioactive
materials have caught the attentions of the researchers, including
poly(lactic-co-glycolic acid) (PLGA) [45], poly(ethylene glycol)-
poly(lactic acid) (PEG-PLA) [46], polyethylene imine (PEI) [47],
poly(b-amino ester)s (PBAEs) [48] and so on. They could generally
protect the free therapeutic drugs during the transportation and
provide long circulation. Moreover, they could be modiﬁed with
speciﬁc targets in brain tumor cells and tumor microenvironment
for targeting delivery. For instances, the brain vascular endothelial
cells and glioblastoma cells overexpressed many receptors,
including low-density lipoprotein receptor [49,50], IL-13 receptor
[51,52], transferrin receptor [53,54] and nicotine acetylcholine re-
ceptor [55], which could be acted as targets for drug delivery to the
brain [43,56]. However, the anti-tumor efﬁciency and median sur-
vival time varied due to the structures of polymers and constitutes
of nanoparticles. The deeper comprehension of inﬂuence on theefﬁciency should help us design more effective bioactive materials
and develop novel approaches applied for glioblastoma therapy.4.1. Poly(lactic-co-glycolic acid) (PLGA)
PLGA was a copolymer prepared by ring-opening polymeriza-
tion of cyclic dimers of lactic acid and glycolic acid. It had been used
in FDA approved therapeutic devices due to its biocompatibility and
biodegradability. It had been applied in many delivery systems
against various diseases, including tumors. Also, the PLGA nano-
particles prepared by nano-emulsion could be played as efﬁcient
carriers across the blood-brain barrier [45,57,58]. For example, a
cyclic nine amino peptide, CRTIGPSVG (CRT), was introduced into
poly(ethylene glycol)-poly(D, L-lactic-co-glycolic acid) (PEG-PLGA)
[59], with a ﬁnal diameter of 118.8 nm. The CRT peptide was able to
bind to a complex of transferrin-transferrin receptor (Tf-TfR) by
functionally mimic iron and facilitate deep penetration into the C6
glioma spheroids, with 2.8-fold as that of non-target nanoparticles.
The enhanced penetration prolonged survival of mice bearing C6
glioma. The median survival time of the treated groups (CRT-NP-
PTX) extended to 46 days, with 214% over the control group. While
the median survival time of non-target group (NP-PTX) was 33
days, reaching 153% over that of the control group.
The PLGA nanoparticles exhibited long circulation and deeper
penetration in glioma spheroids. However, for the in vivo distri-
bution, higher concentration of the injected nanoparticles accu-
mulated in liver and spleen [57]. This greatly reduced the sufﬁcient
drug entry into brain tumor. Considering the position and charac-
teristics of glioblastoma, proper guide and optimized size might
promote the drug concentration in glioblastoma tissues.4.2. Poly(lactic acid) (PLA)
Lactic acid was a compound emerging in the process of meta-
bolism. The formed polymer, poly(lactic acid) (PLA), was a biode-
gradable and hydrophobic polymer, which could be used as a
carrier for hydrophobic chemical drugs. And it had been applied in
clinical trials for anti-tumor research. For example, monomethoxy
poly(ethylene glycol)-block-poly(D, L-lactide) (mPEG-PDLLA)
loaded with paclitaxel formed the Genexol®-PM [60]. The formu-
lation got into clinical trials and had commercially available for
treatment of non-small cell lung cancer (NSCLC), ovarian cancer
and breast cancer [61,62].
Recently, Jun Chen et al. used the poly(ethylene glycol)-
poly(lactic acid) (PEG-PLA) as paclitaxel (PTX) delivery carriers
[46]. The nanoparticles were functionalized with tLyp-1 peptide,
which had good afﬁnity with neuropilin and facilitated to target
both glioma cells and endothelial cells. After modiﬁcation, the
diameter of the nanoparticle slightly increased from 105.32 nm to
111.30 nm. The tLyp-1-conjugated nanoparticles (tLyp-1-NP)
exhibited greater penetration into the C6 glioma spheroids, with
1.32 folds deeper than that of unmodiﬁed nanoparticles. This
capability enhanced the drug accessing into the solid tumors and
prolonged the medium survival time to 37 days in intracranial C6
glioma mice, while those treated with the saline, Taxol® and un-
modiﬁed NP-PTX were only 18, 23 and 28 days, respectively.
However, the structure of PLA belonged to polyester family,
which was sensitive to esterase. And the degradation by esterase
was not the speciﬁc response in glioblastoma. This might result in
instability of the PLA formulated delivery systems and drug leakage
during the transportation to the brain tumor. Herein, smart struc-
tural design and modiﬁcation are required for proper degradation
rate of these bioactive materials.
Fig. 4. The structures of monomers and synthesis of poly(b-amino ester)s (PBAEs). B: base monomer; S: side chain monomer; E: end-capping monomer. Reprinted with permission
from Ref. [48].
Fig. 5. The structures of PEG-P(Glu), and the synthetic route for the ligand introduced
micelle (cRGD/m). Reprinted with permission from Ref. [76]. Copyright (2013) Amer-
ican Chemical Society.
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With many amino residues, PEI was exploited for gene drug
delivery in 1995 [63]. The buffer capability of PEI over a wide range
of acidic environment facilitated the endosomal escape and
released gene into cytosol [64]. This character enhanced effective
gene delivery into tumor cells. For instance, Xin-Tao Shuai and Ying
Peng's group designed a PEGylated hyperbranched-polyethylene
imine (PEI) with a cell speciﬁc targeting molecule folate (FA-PEG-
PEI) for combination of enzyme (cytosine deaminase)/prodrug (5-
ﬂuorocytosine) therapy and immunotherapy (TNF-related
apoptosis-inducing ligand genes) against rat C6 glioma [65]. Animal
studies showed that the average tumor size of the combined
therapy was signiﬁcantly diminished compared with the controls,
with 53.13mm3 vs 172.52mm3, and demonstrated a longer survival
time course.
Combining with anticancer drug, the gene therapy would result
in enhanced antitumor efﬁcacy for treating with glioblastoma cells.
Weiyue Lu et al. prepared a cyclic RGD peptide (c(RGDyK), cyclic
arginine-glycine-aspartic acid-D-tyrosine-lysine)-poly(ethylene
glycol)-polyethylene imine (RGD-PEG-PEI) as a gene carrier for the
plasmid encoding tumor necrosis factor-related apoptosis-inducing
ligand (pORF-hTRAIL). The c(RGDyK) peptide had a high afﬁnity
binding to integrin avb3, which overexpressed on neovasculature
and U87 glioblastoma cells. Co-delivery of paclitaxel loaded
poly(ethylene glycol)-block-poly(lactic acid) (CDX-PEG-PLA-PTX)
micelles, the median survival prolonged to 33.5 days when treated
with the intracranial glioblastoma [66]. While the CDX-PEG-PLA-
PTX and RGD-PEG-PEI/pORF-hTRAIL single treated groups only
survived for 25.5 and 24.5 days, respectively.
These studies demonstrated that PEI exhibited good gene
binding ability and endosomal escape due to the protonation of
amines. This promoted enhanced effects for the gene drugs. And
the PEI nanoparticles exhibited synergistic effect when combing
with other therapeutic methods. However, due to the great number
of amine groups, the balance between gene binding and toxicity of
PEI should be considered for further studies [67].4.4. Poly(b-amino ester)s (PBAEs)
Poly(b-amino ester)s (PBAEs) are a class of biodegradablepolymer that has been exploited for gene delivery vectors [68].
These polymers could degrade quickly under weak acidic condition
by hydrolytically cleaving the b-amino ester bonds. The unique
characteristic enable effective gene transportation and release for
in vitro and in vivo studies [69].
Seven poly(b-amino ester)s (PBAEs) were reported by Jordan J.
Green and Betty Tyler et al. (Fig. 4). They were evaluated as carriers
for DNA delivery of herpes simplex virus type 1 thymidine kinase
(HSVtk) in a malignant glioma model [48]. The optimized nano-
particle formulation (poly(1,4-butanediol diacrylate-co-4-amino-1-
butanol) end-modiﬁed with 1-(3-aminopropyl)-4-
Fig. 6. The synthetic route of DHA-PEG-pLys-pPhe (a), and DHA-PLys(s-s)P/PTX micelles (b). Reprinted and adapted with permission from Ref. [78]. Copyright (2014) American
Chemical Society.
Fig. 7. The chemical structures and sequences of oligomer 49 and oligomer 727. Reprinted and modiﬁed with permission from Ref. [79].
J. Yang et al. / Bioactive Materials 1 (2016) 29e3834methypiperazine formed nanoparticle with HSVtk DNA, for short:
NP-HSVtk) initiated 106 ± 3% cell death of 9Ls and 96 ± 7% cell
death of F98s when administrated with the prodrug ganciclovir
(GCV). And the systemic administration led to a signiﬁcant pro-
longed survival compared with that of the untreated control group
(p ¼ 0.0012) in a 9L glioma model.
The unique structure of poly(b-amino ester)s promoted cellular
uptake and endosomal escape of gene drugs for anti-tumor therapy
[69]. But single formulation of gene nanoparticles was not sufﬁcient
to completely kill the malignant tumors. Suitable targets and
combination strategy should be considered for effective therapy forglioblastoma.
4.5. Polypeptide
Self-assembled polypeptides were widely applied for improved
antitumor drug delivery and studied in preclinical and clinical trials
due to their excellent biodegradability and biocompatibility [70,71].
Like poly(ethylene glycol)-poly(L-glutamic acid) (PEG-P(Glu)), it
had been used for delivery of cisplatin (the formulation name: NC-
6004), dichloro-(1, 2-diaminocyclohexane)platinum (II) (DACHPt,
the formulation name: NC-4016) and 7-ethyl-10-hydroxy-
J. Yang et al. / Bioactive Materials 1 (2016) 29e38 35camptothecin (SN38, the formulation name: NK012) in clinical
trials [72e75]. When bound with the drug, the PEG-P(Glu) could
form micelles in the aqueous phase, with the hydrophilic regions
spread outside and hydrophobic regions aggregated in the center.
After modiﬁed with cyclic Arg-Gly-Asp (cRGD) peptide ligand
(Fig. 5) [76], a target for endothelial cells and glioblastoma cells (e.g.
the U87MG cell line) [77], the micelle (cRGD/m) produced exhibi-
ted relatively small diameters, between 27 and 31 nm, with a
narrow polydispersity. This feature made the micelle bypass the
blood-tumor barriers and penetrate into glioblastoma via cRGD-
mediated transvascular transport. The tumor of the treated group
(cRGD/m) was observed 5-fold inhibition compared to those
treated with oxaliplatin and non-targeting group (cRAD/m) in
orthotropic U87MG glioblastoma model.
Recently, Chen Jiang et al. developed an amphiphilic poly-
peptide poly(ethylene glycol)-polylysine-polyphenylalanine (PEG-
pLys-pPhe) for paclitaxel delivery (Fig. 6) [78]. The copolymer
modiﬁed with dehydroascorbic acid (DHA), which was substrate of
glucose transporter isoform 1 (GLUT1) and facilitated glioma-
targeting. Moreover, the amino groups on pLys block were cross-
linked to stabilize the micelle structures during blood circulation
and trigger release in tumor cellular condition. The micelles had a
diameter of 47 nm with a very narrow polydispersity. With this
smart nanodevice (DHA-PLys(s-s)P/PTX), the drug accumulation in
tumor sites was 2.36-fold increased than non-targeting groups at
8 h. And the survival time was markedly prolonged to 46 days in
intracranial U87 glioma-bearing mice, while free drug Taxol and
non-cross-linked micelles DHA-PLysP/PTX had only 25.5 and 36.5
days, respectively.
Later, Chen Jiang and Ernst Wagner et al. developed a peptide-
like oligomer, oligomer 49 (Fig. 7), as a siRNA carrier for gene
silencing in U87 glioma cells [79]. This biomimetic polymer was
combined with oligomer 727, modiﬁed with angiopep2 peptide, to
exert effective targeting and accumulation. The formulation
(angiopep-PEG/siRNA) suppressed 70% BAG3 (Bcl-2 associated
athanogene 3) expression in vivo, while the control group (PEG/
siRNA) only exhibited nearly 50% suppression.
These biomimic polypeptide-based nanoparticles exhibited
good biocompatibility [80], and better performance againstFig. 8. Free camptothecin (CPT) is incorporated with a-lipoic acid (ALA) and tetra(ethyle
assembly to CPT nanoprodrug (b). Reprinted and adapted with permission from Ref. [84]. Cglioblastoma. Some of them have stepped into clinical trials [74].
But the ratio between the peptide segment and polymer segment
should be optimized to accommodate drug delivery into brain
cancer. Moreover, unlike other biomaterials, most of the poly-
peptide had the corresponding secondary structures. This property
also played its role on the biological application as drug carriers,
and should be put further comprehension on the relationship be-
tween the secondary structures and the properties of the
polypeptide.4.6. Prodrug-based nanoparticles
Nanoparticles composed with various polymers obtained
impressive achievements in drug delivery for anticancer therapy.
However, a great deal of inert materials was applied as drug carriers
and markedly reduced the drug-loading of nanoparticles [81]. To
resolve this problem, Youqing Shen et al. utilized a hydrophobic
therapeutic drug as a component of drug carriers [82,83]. This
strategy not only greatly promoted drug-loading, but also reduced
inert materials in nanoparticles, which might cause side-effect to
human body. Recently, John S. Yu's group prepared a reactive ox-
ygen species (ROS)-responsive prodrug of camptothecin (CPT-TEG-
ALA), and assembled into a nanoprodrug by spontaneous nano-
emulsiﬁcation with a-tocopherol (Fig. 8) [84]. The nanoprodrug
exhibited a diameter of 220 nm, and inhibited 80% tumor growth in
subcutaneous U87 glioma xenograft mice model. Moreover, the
median survival time was signiﬁcantly extended to 72.5 days
against intracranial U87 tumor compared with irinotecan (41.0
days) and control groups (40.5 days).
Prodrug-based nanoparticles exhibited good performance
against gliobalstoma as the therapeutic drug carriers. They greatly
enhanced the drug-loading with less inert materials. Considering
the unique feature of the tumor in brain, suitable targets should be
introduced into the nanoparticles for better guidance [85,86]. Most
of the targets, like cRGD and TAT peptide, had similar or larger
molecular weight than the prodrugs. Herein, unlike other drug
carriers, the inﬂuence on the functionality might be huge for the
prodrug-based nanoparticles when conjugating with the targets.ne glycol) (TEG) into prodrug CPT-TEG-ALA (a). CPT-TEG-ALA and a-tocopherol self-
opyright (2013) American Chemical Society.
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Comparing with other tumors, glioblastoma possesses inherent
barriers for therapeutic drugs due to its individual position. To
overcome these obstacles, numerous bioactive materials are
applied as delivery carriers and reported over the years. The drug
formulation with these materials exhibits a certain extent of anti-
glioblastoma effect and extends the median survival time
compared with the free therapeutic drug. These bioactive materials
self-assemble to nanoparticles with a wide range of diameters, and
provide protection and long circulation of the chemotherapeutic
drugs for in vivo transportation. The diverse structures of the ma-
terials ensure a controllable release by various tailoring, which is
suitable for distinctive tumor environment. Moreover, these drug
delivery systems greatly reduce toxicity to normal tissues in
compare with free drugs. However, as we seen from the above-
mentioned delivery systems, these materials need a proper guid-
ance for more effective and accurate targeting to glioblastoma. The
individual targets for the intracranial tumors have been summa-
rized in other reviews [85,87]. Modiﬁed with the speciﬁc targets
could promote the selective accumulation in brain and tumor cells.
All these factors exert synergistic effect for glioblastoma therapy
and make us step closer to clinical studies and application.
The route of drug crossing the brain barriers, delivering into
tumor cells and performing their functions is a complicated phys-
iological and biological process. And the tumor heterogeneity is a
marked feature of glioblastoma. For example, some tumor regions
are hypoxic and necrotic, while others exhibit more proliferative or
vascularized [88]. These phenotypic features constructed a
complicated tissue. The intratumor heterogeneity and inherent
molecular complexity of glioblastoma urgently needed a rational
combination therapy [89]. Pharmacodynamics failure in bio-
distribution in the brain tumor region due to BBB/BTB made the
adequate drug delivery a critical challenge in glioblastoma treat-
ment. Completely comprehension of the detail delivery pathway to
glioblastoma will help us to construct rational delivery vectors for
therapeutic drugs.
Another potential strategy to further improve the effect of
glioblastoma therapy is to combine chemotherapy with immuno-
therapy. Immunotherapy has emerged as a potential and perspec-
tive treatment for brain cancer [90]. Recently, Jonathan Kipnis's
group proved the existence of lymphatic vessels in the central
nervous system [91]. This discovery provided theory foundation
and new light on the immunotherapy for brain cancers. The
immunotherapy could speciﬁcally kill the cancer cells in cellular
level without damaging the normal brain tissue, and provide a
long-term immune surveillance against the recurrence [92]. The
recent achievement with immunotherapy in the treatment against
glioblastoma sparks widespread interests and stimulates to
develop various immunotherapeutic strategies [93]. For example,
ex-vivo matured dendritic cells (DCs) pulsed with tumor lysates
and glioma-associated antigens have been extensively studied and
proceeded to clinical trials [94,95]. Later, a glioblastoma associated
peptide vaccine, EGFR variant III (EGFRvIII) peptide, was reported to
induce better progression-free survival and longer overall survival
(26 months vs 15 months) comparing with the controls in patients
with newly diagnosed glioblastoma [96]. The immunotherapy in-
spires the whole immune system and ﬁghts for glioblastoma cells.
This is a completely different therapeutic route from the chemo-
therapy and a potential therapeutic treatment for the brain tumors.
Herein, from the above description, proper targeting and
rational design of therapeutic drugs delivery systems should be
very important for efﬁcient chemotherapy. This needs us to get
more comprehension with molecular biology of the progression
and composition of glioblastoma, and the surroundingmicroenvironment. The more rational drug delivery formulation
with biomaterials are designed with the deeper understanding of
these processes. Moreover, combining the chemotherapy with
immunotherapy, activating the immune response and immune
surveillance against the tumor cells, will provide a promising
strategy for clearing up the glioblastoma and inhibiting recurrence.
This two-pronged strategy will get unexpected harvest against the
glioblastoma.
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